Home

Sarepta Therapeutics, Inc. - Common Stock (SRPT)

15.81
-8.64 (-35.34%)
NASDAQ · Last Trade: Nov 4th, 9:47 AM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Insperity Posts Downbeat Q3 Results, Joins IAC, Archer-Daniels-Midland And Other Big Stocks Moving Lower In Tuesday's Pre-Market Sessionbenzinga.com
Via Benzinga · November 4, 2025
Tuesday's pre-market session: top gainers and loserschartmill.com
The US market session of Tuesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Via Chartmill · November 4, 2025
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga.com
Via Benzinga · November 4, 2025
Dow Futures Edge Lower On Pullback Fears: PLTR, SRPT, TSLA, AMD Among Stocks To Watchstocktwits.com
While Dow Jones futures were down by 0.72% at the time of writing, the S&P 500 futures fell 1.02%.
Via Stocktwits · November 4, 2025
Sarepta Therapeutics Stock Crashes After-Hours On DMD Trial Failure, Q3 Print — Retail Still Sees Long-Term Comebackstocktwits.com
Via Stocktwits · November 3, 2025
Earnings Scheduled For November 3, 2025benzinga.com
Via Benzinga · November 3, 2025
Why Upwork Shares Are Trading Higher By Over 22%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · November 4, 2025
Sarepta Therapeutics Stock Is Tumbling After The Close: Here's Whybenzinga.com
Sarepta shares are plunging in extended trading Monday after the company reports third-quarter results and provided an update on its ESSENCE study.
Via Benzinga · November 3, 2025
These stocks are moving in today's after hours sessionchartmill.com
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Via Chartmill · November 3, 2025
A Peek at Sarepta Therapeutics's Future Earningsbenzinga.com
Via Benzinga · October 31, 2025
Sarepta Crashes After Two Muscular Dystrophy Drugs Fail Confirmatory Testsinvestors.com
Sarepta stock crashed Monday after the biotech company said two of its muscular dystrophy drugs failed confirmatory tests.
Via Investor's Business Daily · November 3, 2025
12 Health Care Stocks Moving In Monday's After-Market Sessionbenzinga.com
Via Benzinga · November 3, 2025
Tradr Unleashes 2X Single-Stock Gold ETFs, Reshaping Short-Term Gold Investment Landscape
New York, NY – October 23, 2025 – Tradr, a prominent innovator in the Exchange-Traded Fund (ETF) market, has today significantly expanded its product suite with the launch of nine new single-stock 2X leveraged ETFs. This marks Tradr's most extensive collection of such launches to date, pushing its total lineup to 48
Via MarketMinute · October 23, 2025
Top Stocks With Earnings This Week: Joby, IonQ, AMD and Morebenzinga.com
Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Friday.
Via Benzinga · November 3, 2025
Tradr Launches 9 Single-Stock 2X ETFs With First-Of-Its-Kind OpenDoor, Gold And AI Exposurebenzinga.com
The new ETFs include the first-of-their-kind gold and AI plays, giving traders targeted exposure without using margin or complex options.
Via Benzinga · October 23, 2025
Tradr Debuts Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULFstocktwits.com
Funds seek to provide 200% long exposure on a variety of industry leaders
Via Stocktwits · October 23, 2025
What's Going On Sarepta Stock On Wednesday?benzinga.com
Sarepta prepares to present new data on Duchenne and limb-girdle muscular dystrophy gene therapy programs this week.
Via Benzinga · October 8, 2025
Why Sarepta Therapeutics Stock Is Rising Nearly 5% Premarketstocktwits.com
Investors turned upbeat ahead of Sarepta’s data presentations in Vienna, where the company is expected to share new Duchenne muscular dystrophy results and updates from its broader gene therapy pipeline.
Via Stocktwits · October 8, 2025
Leap Therapeutics (LPTX) Plummets Over 20% Amidst Profit-Taking and Volatility Ahead of Key Clinical Data
Boston, MA – October 3, 2025 – Leap Therapeutics, Inc. (NASDAQ: LPTX) experienced a sharp downturn in its stock performance today, with shares falling by over 20% in intraday trading. This significant decline marks a notable correction for the biotechnology company, which had seen its stock surge dramatically in the preceding days,
Via MarketMinute · October 3, 2025
Taysha Gene Therapies, Canaan, Ondas Holdings And Other Big Stocks Moving Higher On Thursdaybenzinga.com
U.S. stocks were mixed, with the Dow Jones index falling more than 50 points on Thursday.
Via Benzinga · October 2, 2025
Incannex Healthcare (NASDAQ: IXHL) Braces for Volatility as Q4 Earnings Loom: Options Traders Eye Strategic Plays
Melbourne, Australia – September 27, 2025 – Incannex Healthcare Limited (NASDAQ: IXHL) is on the cusp of a pivotal week, with its Q4 2025 earnings report scheduled for release on Monday, September 29, 2025, before market open. This highly anticipated announcement is expected to inject significant volatility into the stock, with analysts
Via MarketMinute · September 27, 2025
This Sarepta Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Mondaybenzinga.com
Via Benzinga · September 22, 2025
The Pharmaceutical Revolution: AI, Gene Therapies, and Obesity Drugs Reshape a Trillion-Dollar Market
The global pharmaceutical sector stands at the precipice of a monumental transformation, driven by an unprecedented convergence of scientific breakthroughs, technological innovation, and evolving market demands. New drug developments, particularly in sophisticated biologics, groundbreaking gene therapies, and blockbuster obesity treatments, are fundamentally altering therapeutic paradigms. Simultaneously, the pervasive integration of
Via MarketMinute · September 19, 2025
Expert Outlook: Sarepta Therapeutics Through The Eyes Of 43 Analystsbenzinga.com
Via Benzinga · September 15, 2025
2 Beaten-Down Stocks to Avoid Right Nowfool.com
These once high-flying stocks no longer seem to have promising prospects.
Via The Motley Fool · September 5, 2025